Demcizumab
Based on 1 Customer Validation
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.37%
- CAS No.: 1243262-17-0
- 분자량:145.36 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-P99320
TarextumabAnti-Notch2/3 Monoclonal Antibody -
HY-P99258
BrontictuzumabNotch1 Inhibitor -
HY-137471
RBPJ Inhibitor-1RBPJ Inhibitor -
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-P99575
Tarlatamabanti-DLL3/CD3 BiTE antibody -
HY-P99043
RovalpituzumabDLL3 Monoclonal Antibody -
HY-135145
LimantrafinNotch Inhibitor -
HY-15860
FLI-06Notch Inhibitor -
HY-P99377
NavicixizumabAnti-VEGF/DLL4 Antibody -
HY-15670
BMS-906024γ-secretase Inhibitor -
HY-120782
Yhhu-3792Notch Activator -
HY-100431
IMR-1Notch Inhibitor
Biological Activity
제품 설명
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
DLL4
In Vitro
Demcizumab (0-100 μg/mL) binds to human DLL4 but not murine DLL4, and blocks DLL4 binding to Notch1 receptor in a FACS-binding assay[3].
Demcizumab (20 μg/mL, 48 h) reduces HES1 and DTX1 mRNA expression in PDTALL cells[4].
Demcizumab (0-80 μg/mL, 1 or 2 or 3 days) promotes cell death and early apoptosis in PDTALL13 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PDTALL13 (patient-derived T-ALL 13) cell
-
Concentration:0, 0.5, 1, 5, 10, 20, 40, 80 μg/mL
-
Incubation Time:1 or 2 or 3 days
-
Result:Dose-dependently inhibited cell viability.
In Vivo
Demcizumab is efficacious alone or in combination with Irinotecan (7.5 mg/kg) in OMP-C8 colon tumors[3].
Demcizumab (20 mg/kg/week, i.p.) increases mice survival in irradiated NRG mice injected PDTALL13 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:KRASWT and KRASMT CRC xenografts[2]
-
Dosage:10 mg/kg, together with Irinotecan (HY-16562) (7.5 mg/kg)
-
Administration:Intraperitoneal injection (i.p.), once a week
-
Result:Resulted in tumor regression at day 20.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
NP_061947.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG2 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 HUVEC cells with Demcizumab (HY-P99261, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1243262-17-0
-
Appearance Liquid
-
분자량 145.36 kDa
-
Color Colorless to light yellow
-
SMILES
[Demcizumab]
-
Synonyms
OMP 21M18
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. [Content Brief]
[2]. Fischer M, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71:1520-5. [Content Brief]
[3]. Hoey T, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168–77. [Content Brief]
[4]. Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Demcizumab Related Classifications
HY-P99261 Related Classifications
Powered by Bioz